A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi
A phase 2 trial of Darolutamide in prostate cancer, run by Bayer, now recruiting.
Overview
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. is a phase 2 interventional study registered as NCT07450599 by Bayer, with 250 participants planned, started 2026-04-27 and due to reach its primary completion in 2028-10-15. Interventions recorded: Darolutamide, ADT. Conditions listed: High-risk Localized Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer
Shares Darolutamide, Bayer, Prostate cancer.
- TrialStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Shares Darolutamide, Bayer.
- TrialA Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Shares Darolutamide, Prostate cancer.
- TrialTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
Shares Darolutamide, Prostate cancer.
- TrialA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Shares Darolutamide, Prostate cancer.
- TrialGedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Shares Darolutamide, Prostate cancer.
- TrialARASENS
Shares Darolutamide, Prostate cancer.
- TrialStudy of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Shares Darolutamide, Prostate cancer.